Safety, Tolerability and Antiviral Activity of the Antisense Oligonucleotide Bepirovirsen in Patients with Chronic Hepatitis B: A Phase II Randomized Controlled Trial

Investigators evaluated the safety and activity of an antisense oligonucleotide targeting hepatitis B virus (HBV) RNA in both treatment-naïve and virally suppressed individuals with chronic HBV infection.
[Nature Medicine]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Monoclonal Antibodies from Humans with Mycobacterium tuberculosis Exposure or Latent Infection Recognize Distinct Arabinomannan Epitopes

The authors generated human IgG mAbs to AM/LAM from B cells of two asymptomatic individuals exposed to or latently infected with M. tuberculosis.
[Communications Biology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Infectious Disease in an Era of Global Change

The authors consider the extent to which recent global changes have increased the risk of infectious disease outbreaks, even as improved sanitation and access to health care have resulted in considerable progress worldwide.
[Nature Reviews Microbiology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Characterization of SARS-CoV-2-Specific Humoral Immunity and Its Potential Applications and Therapeutic Prospects

Scientists summarize the characteristics of the humoral immune response after SARS-CoV-2 infection and further emphasize the potential applications and therapeutic prospects of SARS-CoV-2-specific humoral immunity and the critical role of this immunity in vaccine development.
[Cellular & Molecular Immunology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Lessons in Self-Defence: Inhibition of Virus Entry by Intrinsic Immunity

Investigators summarize what is known and what remains to be understood about the intrinsic factors that form the first line of defence against virus infection.
[Nature Reviews Immunology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Features of Repertoire Diversity and Gene Expression in Human Cytotoxic T Cells Following Allogeneic Hematopoietic Cell Transplantation

Scientists showed the features of repertoire diversity and the gene expression profile of HLA-A24 cytomegalovirus-specific cytotoxic T cells in actual recipients according to the cytomegalovirus reactivation pattern.
[Communications Biology]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Safety, Pharmacokinetics and Antiviral Activity of PGT121, a Broadly Neutralizing Monoclonal Antibody against HIV-1: A Randomized, Placebo-Controlled, Phase 1 Clinical Trial

Researchers performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg–1 in HIV-uninfected adults and HIV-infected adults on antiretroviral therapy.
[Nature Medicine]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase IIIb Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Arcturus Therapeutics Holdings, Inc. announced that the Vietnam Ministry of Health has approved initiation of the Phase IIIb part of the placebo-controlled, observer-blind Phase I/II/III clinical trial of ARCT-154 self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant and other variants of concern.
[Arcturus Therapeutics Holdings, Inc.]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the US FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

Merck and Ridgeback Biotherapeutics announced that Merck has submitted an Emergency Use Authorization application to the FDA for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
[Merck (BusinessWire, Inc.)]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate

Scientists characterized the immunology of neonates born to mothers with confirmed SARS-CoV-2 infection during pregnancy. They showed that maternal SARS-CoV-2 infection affected the neonatal immune system.
[Nature Immunology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US

AstraZeneca has submitted a request to the FDA for an Emergency Use Authorization for AZD7442, its long-acting antibody combination, for prophylaxis of symptomatic COVID-19.
[AstraZeneca (BusinessWire, Inc.)]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share